• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lantheus Announces CEO Succession Plan

    1/23/24 7:45:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email

    Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024

    Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors

    BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Company has appointed Brian Markison, current Board Chair and industry veteran, to the position of Chief Executive Officer (CEO), effective as of March 1, 2024. He will also continue as a member of Lantheus' Board of Directors, where he has served for the past 11 years. Mary Anne Heino, who has successfully led and grown the Company for the past nine years, will retire as CEO on March 1, 2024 and assume the role of Chair of the Board of Directors as part of a deliberate CEO succession process. As part of this leadership transition, Mr. Markison will assume the role of Executive Chair of the Board immediately until his CEO appointment in March, and Board Member Julie McHugh will become Lead Independent Director effective immediately.

    "Brian is perfectly suited to lead Lantheus as the Company enters its next phase of growth. He has held the Chair role for more than 10 years and in that role has overseen Company strategy. He knows our exceptional Executive Team well and brings decades of leadership experience as the CEO of public companies with development, commercialization and manufacturing expertise, including in oncology and neurology therapeutics," said Mary Anne Heino. "It has been my honor to lead Lantheus over the past nine years, and I am extremely proud of what we have accomplished. Our leadership as a radiopharmaceutical-focused company and the contributions Lantheus has made to precision diagnostics have aided healthcare providers and their patients around the world. We have an incredibly talented team at Lantheus, and I look forward to serving as Chair and continuing to partner closely with Brian and the Executive Team as we focus on our Purpose to Find, Fight and Follow disease to deliver better patient outcomes."

    Mr. Markison has 40 years of healthcare experience, including executive roles at King Pharmaceuticals, Fougera Pharmaceuticals and RVL Pharmaceuticals plc, as well as senior level roles at Bristol-Myers Squibb. Mr. Markison has maintained a steadfast focus throughout his career on oncology, virology, and diagnostics, leading the successful commercial introduction of numerous therapeutics, ranging from chemotherapy to biologics, across major global markets. He has been a member of the Lantheus Board of Directors since September 2012 and has served as Chairman since January 2013. Mr. Markison most recently served as CEO and Director of RVL Pharmaceuticals plc, formerly Osmotica Holdings, SCSp. He serves on the Board of Directors of Cosette Pharmaceuticals and is a Director of the College of New Jersey.

    "On behalf of the Lantheus Board of Directors, I would like to sincerely thank Mary Anne for her remarkable leadership and contributions that helped drive Lantheus' success throughout her tenure as CEO," said Ms. McHugh. "We are energized by the experience and expertise Brian brings to this role, and confident in the Company's ability to build on Mary Anne's legacy by strengthening its leading position in the industry and executing on the compelling opportunities ahead."

    Under the leadership of Ms. Heino and the Executive Team, Lantheus marked numerous achievements, establishing a strong foundation for long-term growth. These included the development and commercialization of the leading prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent for prostate cancer. She led the successful acquisition of Progenics, expanding Lantheus' lines of business from diagnostic imaging agents to a diverse range of diagnostics, radiotherapeutics and artificial intelligence solutions. Most recently, she executed a strategic collaboration with POINT Biopharma, enhancing Lantheus' radiopharmaceutical portfolio with two late-stage therapeutic candidates; the acquisition of Cerveau Technologies, Inc., expanding the company's imaging pipeline into Alzheimer's disease; and strategic agreements with Perspective Therapeutics, Inc., a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body.

    "I want to thank the Board of Directors for this tremendous opportunity to lead Lantheus as CEO," said Brian Markison. "Lantheus has a dynamic team dedicated to delivering life-changing science to patients and providers across the globe, and we are poised to enhance our growth trajectory by unlocking the potential of our innovative platform to improve patient outcomes and lives. I could not be more pleased to make this transition from Chair to CEO and lead the company as we execute on the many opportunities that lie ahead."

    Preliminary Full Year 2023 Revenue

    As previously announced on January 9, 2024, worldwide revenue for the full year 2023 is expected to be in the range of $1.295 - 1.297 billion, which includes a $15 million RELISTOR milestone achievement, compared with $0.935 billion for the full year 2022, which would represent an increase of approximately 38 - 39% over the prior year period, exceeding the Company's previously issued guidance range of $1.255 - 1.270 billion.

    These preliminary results are unaudited and remain subject to adjustment. Lantheus will provide its fourth quarter and full year 2023 financial results, and further details related to its 2024 financial expectations, in late February 2024.

    About Lantheus

    Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

    Safe Harbor for Forward-Looking and Cautionary Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "build," "capture," "continue," "executing," "expected," "guidance," "poised," "will," "would" and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

    Contacts:

    Mark Kinarney

    Vice President, Investor Relations

    978-671-8842

    [email protected]

    Melissa Downs

    Senior Director, External Communications

    646-975-2533

    [email protected]



    Primary Logo

    Get the next $LNTH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    3/8/2023$120.00Mkt Outperform
    JMP Securities
    11/30/2022Outperform
    SVB Leerink
    More analyst ratings

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

      BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

      7/23/25 8:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

      BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

      7/22/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

      BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 21-24, 2025, in New Orleans, LA. Presentation details are as follows: Oral Presentations Date & Time: Tuesday, June 24, 2025; 2:30 – 3:35 PM CTSession Number: SS39Session Title: Advancing Radiopharmaceutical Production, Qu

      6/11/25 4:01:00 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Blanchfield Paul covered exercise/tax liability with 518 shares, decreasing direct ownership by 0.46% to 111,274 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      7/17/25 4:30:23 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Officer Niedzwiecki Daniel sold $472,440 worth of shares (6,000 units at $78.74), decreasing direct ownership by 6% to 87,057 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/17/25 4:31:48 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Mchugh Julie sold $423,771 worth of shares (5,192 units at $81.62), decreasing direct ownership by 17% to 25,962 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:33:01 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Lantheus Holdings with a new price target

      Goldman initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $143.00

      12/18/24 7:37:47 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Redburn Atlantic initiated coverage on Lantheus Holdings with a new price target

      Redburn Atlantic initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $175.00

      9/3/24 8:07:35 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JMP Securities reiterated coverage on Lantheus Holdings with a new price target

      JMP Securities reiterated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $130.00 from $100.00 previously

      7/10/24 3:24:56 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    SEC Filings

    See more
    • SEC Form 8-K filed by Lantheus Holdings Inc.

      8-K - Lantheus Holdings, Inc. (0001521036) (Filer)

      7/22/25 7:31:48 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 144 filed by Lantheus Holdings Inc.

      144 - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/9/25 10:06:49 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

      SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/6/25 11:59:42 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

      3/8/24 11:24:53 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

      BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

      7/22/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

      BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

      1/30/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Financials

    Live finance-specific insights

    See more
    • Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

      BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

      7/23/25 8:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

      Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year

      5/7/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

      BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About Lan

      4/23/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lantheus Holdings Inc.

      SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 8:21:14 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

      SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 3:29:28 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Lantheus Holdings Inc.

      SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

      2/14/24 1:18:20 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care